Brief: Oncolytics Biotech® Reports Durable Responses In Second-Line Ras-Mutant Mss Colorectal Cancer
04/05/2026 14:09
May 4 (Reuters) - Oncolytics Biotech Inc ONCY.O: ONCOLYTICS BIOTECH® REPORTS DURABLE RESPONSES IN SECOND-LINE RAS-MUTANT MSS COLORECTAL CANCER ONCOLYTICS BIOTECH INC - ENGAGED WITH FDA ON ACCELERATED APPROVAL PATHWAY FOR 2L RAS-MUTANT MSS MCRC ONCOLYTICS BIOTECH INC - PELAEOREOREP COMBINATION SHOWS 19.5-MONTH MEDIAN DURATION OF RESPONSE IN 2L KRAS-MUTANT MSS MCRC ONCOLYTICS BIOTECH INC - 2L KRAS-MUTANT MSS MCRC DEMONSTRATES 3-4X IMPROVEMENT IN DURATION OF RESPONSE VERSUS. HISTORICAL 4-6 MONTH BENCHMARK Source text: ID:nGNXy6jXM Further company coverage: ONCY.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Oncolytics Biotech
See all newsBrief: Oncolytics Biotech Expects Final Cohort 4 Results Of Goblet Study In Q4 2026
Brief: Oncolytics Biotech® Secures Patent Protection To Late 2040S And Provides Intellectual Property Portfolio Update
Brief: Oncolytics Biotech® Aligns With FDA On Registrational Path For Second-Line Ras-Mutant Mss Colorectal Cancer
Brief: Oncolytics Biotech Announces New US Patent For Pelareorep Manufacturing Process
Brief: Oncolytics Biotech® Reports Durable Responses In Second-Line Ras-Mutant Mss Colorectal Cancer